Attovia Seeks Funds to Challenge Big Pharma
Attovia Therapeutics wants to raise money to develop new medicines that could compete with major drugs from Sanofi and Regeneron.
Attovia Therapeutics just filed for an initial public offering, an IPO. This move helps the company raise money from investors. It wants to fund new treatments. These treatments target serious conditions.
One key target is a drug that works like Dupixent. Dupixent is a top-selling medicine from Sanofi and Regeneron. It treats conditions like eczema and asthma. Attovia also aims to compete with Nemluvio from Galderma. Attovia hopes to create new options for patients.
The money from the IPO will help Attovia develop its drug pipeline. This includes its proposed Dupixent rival. It pushes medical science forward. The company seeks to bring new, needed medicines to market. This could offer new choices for patients.
Source: FierceBiotech